Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial

Main Article Content

RB Warren
C Conrad
P Foley
L Iversen
RG Langley
G Kokolakis
L Davis
V Vanvoorden
S Wiegratz
JF Merola


bimekizumab, secukinumab, psoriasis, moderate to severe, BE RADIANT, phase 3, clinical trial, efficacy




1. Papp KA et al. J Am Acad Dermatol 2018;79:2

2. Tada Y et al. J Dermatol 2021;48:1665–74

3. Rasmussen MK et al. Acta Derm Venereol 2019;99:158–63

4. Reich K et al. N Engl J Med 2021;385:142–52

5. Mahil SK et al. Br J Dermatol 2020;182:1158–66

Most read articles by the same author(s)

1 2 > >>